Protease-activated receptor-mediated platelet aggregation in acute coronary syndrome patients on potent P2Y<sub>12</sub> inhibitors

Patricia P. Wadowski MD<sup>1</sup> | Joseph Pultar LLM<sup>1</sup> | Constantin Weikert<sup>1</sup> | Beate Eichelberger<sup>2</sup> | Benjamin Panzer MD<sup>2</sup> | Kurt Huber MD<sup>3</sup> | Irene M. Lang MD<sup>1</sup> | Renate Koppensteiner MD<sup>1</sup> | Simon Panzer MD<sup>2</sup> | Thomas Gremmel MD<sup>1,4</sup>

<sup>1</sup>Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria
<sup>2</sup>Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria
<sup>3</sup>3rd Department of Medicine, Cardiology and Intensive Care Medicine, Chest Pain Unit, Wilhelminenhospital, Vienna, Austria
<sup>4</sup>Department of Internal Medicine, Cardiology and Nephrology, Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria

Abstract

**Background:** Despite the increasing use of potent P2Y<sub>12</sub> inhibitors, further atherothrombotic events still impair the prognosis of many acute coronary syndrome (ACS) patients. This may in part be attributable to intact platelet aggregation via the human thrombin receptors protease-activated receptor (PAR)-1 and PAR-4.

**Objective:** We studied PAR mediated platelet aggregation in ACS patients following percutaneous coronary intervention (PCI) with stent implantation in a cross-sectional study.

**Methods:** Platelet aggregation to ADP as well as to the PAR-1 agonist SFLLRN and the PAR-4 agonist AYPGKF was assessed by multiple electrode aggregometry in 194 ACS patients on dual antiplatelet therapy with aspirin and either prasugrel (n = 114) or ticagrelor (n = 80) 3 days after PCI.

**Results:** Based on the consensus cutoff value, high on-treatment residual platelet reactivity to ADP (HRPR ADP) was observed in only 2 prasugrel-treated patients. Both patients with HRPR ADP had also a normal response to SFLLRN and AYPGKF. Among the 112 prasugrel-treated patients with adequate P2Y<sub>12</sub> inhibition, 50 patients (45%) still had a normal response to SFLLRN, and 70 patients (63%) still had a normal response to AYPGKF. Among the 80 ticagrelor-treated patients with adequate P2Y<sub>12</sub> inhibition, 25 patients (31%) still had a normal response to SFLLRN, and 50 (63%) still had a normal response to AYPGKF.

**Conclusion:** Normal platelet aggregation via PAR-1 and PAR-4 is preserved in many patients with adequate P2Y<sub>12</sub> inhibition by prasugrel and ticagrelor. The present findings may at least in part explain adverse ischemic events despite potent P2Y<sub>12</sub> inhibition.

**KEYWORDS**
antiplatelet therapy, protease-activated receptor 1, protease-activated receptor 4, prasugrel, ticagrelor, platelet aggregation
INTRODUCTION

Dual antiplatelet therapy with aspirin and an ADP P2Y\textsubscript{12} inhibitor is the current standard treatment for patients with an acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) with stent implantation.\textsuperscript{1-5} The newer P2Y\textsubscript{12} receptor antagonists prasugrel and ticagrelor offer more potent platelet inhibition than clopidogrel and were shown to significantly reduce adverse ischemic outcomes following an ACS compared with clopidogrel.\textsuperscript{6,7} However, despite the increasing use of prasugrel and ticagrelor, further antiplatelet therapy still impairs the prognosis of many ACS patients.\textsuperscript{1,8} Recently, Motovska et al\textsuperscript{8} reported the 1-year outcomes of the PRAGUE-18 (Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction) trial including 1230 patients on dual antiplatelet therapy with aspirin and prasugrel or ticagrelor. During the follow-up period of 12 months, adverse ischemic events occurred in 6.6\% of prasugrel- and 5.7\% of ticagrelor-treated patients.\textsuperscript{8} The latter has been explained by the fact that a significant number of patients were switched to clopidogrel after hospital discharge, but might in part also be attributable to intact platelet aggregation via the human thrombin receptors protease-activated receptor (PAR)-1 and PAR-4.\textsuperscript{9-11} Thrombin is a strong endogenous platelet agonist, leading to platelet activation at subnanomolar concentrations.\textsuperscript{12} It acts as a multifunctional serine protease, which activates human platelets predominantly via PAR-1 and, to a lesser extent, PAR-4.\textsuperscript{13-15} PAR-1 is activated by low thrombin concentrations and amplified by PAR-4 signaling as the thrombin concentration rises.\textsuperscript{11,16} Thus, both PAR-1 and PAR-4 need to be blocked for full inhibition of thrombin-induced platelet activation. The activation of platelets by thrombin leads in turn to ADP release, promoting further recruitment, adhesion, and aggregation of activated platelets via stimulation of P2Y\textsubscript{1} and P2Y\textsubscript{12} receptors. Accordingly, P2Y\textsubscript{12} inhibition also affects PAR-mediated platelet aggregation.\textsuperscript{17}

In the past, we have demonstrated that platelets can still be activated via PAR-1 and PAR-4 despite P2Y\textsubscript{12} inhibition by clopidogrel.\textsuperscript{18} In the current study, we sought to investigate if platelet aggregation via PAR-1 and PAR-4 persists in ACS patients receiving the newer and more potent P2Y\textsubscript{12} antagonists following PCI with stent implantation.

METHODS

Study population

The study population consisted of 194 ACS patients on daily aspirin (100 mg/d), and either prasugrel (10 mg/d, n = 114), or ticagrelor (180 mg/d, n = 80) therapy. All study patients were of Caucasian ethnicity. Blood sampling was performed 72 hours after acute PCI with stent implantation. Due to the short half-life of unfractionated heparin, all patients were free of heparin from PCI.\textsuperscript{19} Exclusion criteria were a known P2Y\textsubscript{12} inhibitor or aspirin intolerance (manifested as allergic reactions or gastrointestinal bleeding); a therapy with vitamin K antagonists (phenprocoumon, acenocoumarol, warfarin), rivaroxaban, apixaban, dabigatran, or edoxaban; treatment with nonsteroidal anti-inflammatory drugs, ticlopidine, or dipyridamole; known bleeding disorders; severe hepatic failure; known qualitative defects in platelet function; heparin-induced thrombocytopenia; malignant myeloproliferative disorders; a platelet count <100 000 or >450 000/\mu L; a hematocrit <30\%; and a major surgical procedure within 1 week before enrollment.

The study protocol was approved by the local Ethics Committee of the Medical University of Vienna and was in accordance with the Declaration of Helsinki. Written informed consent was obtained from all study participants.

Blood sampling

Blood was drawn by aseptic venipuncture from an antecubital vein using a butterfly needle (21-gauge, 0.8 × 19 mm; Greiner Bio-One, Kremsmünster, Austria) 72 hours after PCI. To avoid procedural deviations, blood sampling was performed by the same physician applying a light tourniquet, which was immediately released, and the samples were mixed by gently inverting the tubes. The initial 3 mL of blood were discarded to reduce peri-procedural platelet activation. Afterwards, blood was drawn into hirudin-coated tubes (Roche Diagnostics, Mannheim, Germany) for multiple electrode aggregometry (MEA).

Multiple electrode aggregometry

Whole blood impedance aggregometry was performed using the Multiplate analyzer (Roche Diagnostics) as previously described.\textsuperscript{17,18} In brief, hirudin-anticoagulated whole blood was diluted 1:2 with 0.9\% NaCl solution and stirred in the test cuvettes for 3 minutes at 37°C. Thereafter, ADP (P2Y\textsubscript{12} agonist, 6.5 \mu mol/L), SFLLRN (PAR-1 agonist, 32 \mu mol/L) or AYPGKF (PAR-4 agonist, 645 \mu mol/L, all from Roche Diagnostics) was added and aggregation was recorded for 6 minutes. Titration experiments were carried out, increasing the dosages of SFLLRN and AYPGKF, respectively, until both agonists induced platelet aggregation >60 aggregation units (AU) by MEA, but less than maximal response in healthy Caucasian individuals (n = 30). The determined dosages corresponded to the concentrations

Essentials

- Atherothrombotic events still impair the prognosis of many acute coronary syndrome (ACS) patients.
- This may in part be attributable to intact platelet aggregation via protease-activated receptor (PAR)-1 and PAR-4.
- Platelet aggregation was measured 3 days after percutaneous coronary intervention in 194 ACS patients on novel P2Y\textsubscript{12} blockers.
- PAR-mediated platelet aggregation is preserved despite adequate P2Y\textsubscript{12} inhibition.
recommended by the manufacturer. The increase of impedance that was evoked by the adhesion of activated platelets to the electrodes was detected by each sensor unit separately, transformed to AU and plotted against time.

2.4 Statistical analysis

Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS version 24.0; SPSS, Chicago, IL). Median and interquartile range of continuous variables are shown. Categorical variables are given as number (%). We performed the nonparametric Mann-Whitney U-tests to detect differences in continuous variables. The chi-square test was used to assess differences in categorical variables. Spearman correlation was used to test for correlations between platelet aggregation in response to the different agonists. Two-sided P values < 0.05 were considered statistically significant.

3 RESULTS

Clinical, laboratory, and procedural characteristics of the study population are given in Table 1. As expected, ticagrelor-treated patients (n = 80) were older than prasugrel-treated patients (n = 114; P = 0.02) and had significantly higher serum creatinine levels (P = 0.001).

Residual ADP-inducible platelet aggregation was similar in prasugrel- and ticagrelor-treated patients (19 AU [15-23 AU] vs. 20 AU [14-25 AU], P = 0.4; Figure 1A). Likewise, SFLLRN- and AYPGKF-inducible platelet aggregation was similar between prasugrel- and ticagrelor-treated patients (SFLLRN: 68 AU [48-85 AU] vs. 62 AU [47-80], P = 0.2; AYPGKF: 60 AU [44-83 AU] vs. 64 AU [45-78 AU], P = 0.96; Figure 1B,C; Table 2).

Adenosine diphosphate inducible platelet aggregation correlated significantly with both SFLLRN and AYPGKF inducible platelet aggregation in the overall study population (SFLLRN: r = 0.55, P < 0.001; AYPGKF: r = 0.48, P < 0.001; Figure 2A and B) as well as in prasugrel- and ticagrelor-treated patients alone (prasugrel: SFLLRN: r = 0.52, P < 0.001; AYPGKF: r = 0.48, P < 0.001; ticagrelor: SFLLRN: r = 0.6, P < 0.001; AYPGKF: r = 0.5, P < 0.001). All patients with PAR-mediated platelet aggregation in the first quartile also had suppressed platelet aggregation via the P2Y\textsubscript{12} receptor. Patients with PAR-mediated platelet aggregation in the first quartile were defined as patients with low PAR-1 (n = 50) and low PAR-4 (n = 51) mediated platelet aggregation, respectively. Patients with low PAR-mediated platelet aggregation had significantly less platelet aggregation in

| TABLE 1 | Patient characteristics |
|----------|-------------------------|
| Characteristics | Prasugrel (n = 114) | Ticagrelor (n = 80) | P value |
| Age, y | 57 (49-64) | 60 (51-70) | 0.02 |
| Male sex, n (%) | 93 (82) | 62 (78) | 0.49 |
| BMI, kg/m\textsuperscript{2} | 28 (25-31) | 28 (25-30) | 0.72 |
| Medical history | | | |
| Previous myocardial infarction, n (%) | 18 (16) | 13 (16) | 0.87 |
| Hypertension, n (%) | 76 (67) | 57 (71) | 0.47 |
| Hyperlipidemia, n (%) | 87 (76) | 58 (73) | 0.79 |
| Diabetes mellitus, n (%) | 18 (16) | 15 (19) | 0.15 |
| Active smoking, n (%) | 66 (58) | 38 (48) | 0.16 |
| Stent implantation, n (%) | 114 (100) | 80 (100) | 1 |
| Number of stents/patient | 1 (1-2) | 1 (1-2) | 0.21 |
| Laboratory data | | | |
| Serum creatinine, mg/dL | 0.9 (0.76-1.02) | 1 (0.82-1.2) | 0.001 |
| Platelet count, g/L | 222 (194-252) | 226 (187-269) | 0.86 |
| High sensitivity C-reactive protein, mg/dL | 1.3 (0.7-4.3) | 1.2 (0.5-3.4) | 0.18 |
| Hemoglobin, g/dL | 13.9 (13.1-14.7) | 13.6 (12.7-14.6) | 0.42 |
| WBC, g/L | 8.9 (7.9-10.4) | 8.7 (7-10.6) | 0.53 |
| Medication | | | |
| Statins, n (%) | 113 (99) | 79 (99) | 0.8 |
| Beta blockers, n (%) | 110 (96) | 78 (98) | 0.69 |
| ACE inhibitors, n (%) | 96 (84) | 60 (75) | 0.11 |
| Calcium channel blockers, n (%) | 10 (9) | 9 (11) | 0.57 |
| Angiotensin receptor blockers, n (%) | 16 (14) | 18 (23) | 0.13 |

Continuous data are shown as median (interquartile range). Dichotomous data are shown as n (%).

ACE, angiotensin-converting-enzyme; BMI, body mass index; WBC, white blood cells.
WADOWSKI et al.

response to ADP than the remaining patients (PAR-1: 15 AU (10-19 AU) vs. 20 AU (16-25 AU), P < 0.001; PAR-4: 16 AU (10-20 AU) vs 21 AU (16-25 AU), P < 0.001). Further, we observed a strong correlation between SFLLRN- and AYPGKF-inducible platelet aggregation in the overall study population (r = 0.7, P < 0.001; Figure 2C) as well as in prasugrel- and ticagrelor-treated patients alone (prasugrel: r = 0.74, P < 0.001; ticagrelor: r = 0.63, P < 0.001).

Based on the consensus cutoff value of AU ≥47, only 2 prasugrel-treated patients had HRPR ADP. In contrast, 112 patients on prasugrel therapy (98%) and all patients on ticagrelor therapy (100%) had an adequately suppressed response to ADP. The cutoff values for PAR-mediated platelet aggregation were derived from a group of 55 healthy Caucasian volunteers (male/female, 21/34) aged 42 ± 13 years, who served as the control population in a previously published study. For PAR-1 and PAR-4–mediated platelet aggregation, the upper 95% of data obtained in the healthy control population were considered as normal uninhibited platelet aggregation to eliminate possible low outliers. The corresponding cutoff values were AU ≥ 71 for normal PAR-1–mediated platelet aggregation (SFLLRN as agonist) and AU ≥ 54 for normal PAR-4–mediated platelet aggregation (AYPGKF as agonist).

The 2 prasugrel-treated patients with HRPR ADP by MEA also had a normal response to SFLLRN and AYPGKF. Among the 112 prasugrel-treated patients with adequate P2Y12 inhibition, 50 patients (45%) still had a normal platelet response to SFLLRN, 70 patients (63%) still had a normal platelet response to AYPGKF, and 45 patients (40%) had a normal response to both SFLLRN and AYPGKF. Among the 80 ticagrelor-treated patients with adequate P2Y12 inhibition, 25 patients (31%) still had a normal platelet response to SFLLRN, 50 patients (63%) had a normal platelet response to AYPGKF, and 22 patients (28%) had a normal response to both SFLLRN and AYPGKF.

Our study demonstrates that ACS patients with adequate ADP P2Y12 inhibition during antiplatelet therapy with prasugrel or ticagrelor frequently have a normal aggregation response to PAR-1 or PAR-4 stimulation.

We decided to assess platelet aggregation by MEA because MEA is a fast and standardized platelet function assay that can be easily applied in daily clinical routine. Moreover, results obtained by MEA have been associated with adverse outcomes following PCI.20-23

![Figure 1](image1.png)

**TABLE 2** Platelet aggregation following stimulation with SFLLRN and AYPGKF in prasugrel- and ticagrelor-treated patients

|            | Prasugrel (n = 114) | Ticagrelor (n = 80) | P value |
|------------|---------------------|---------------------|---------|
| SFLLRN, AU | 68 (48-85)          | 62 (47-80)          | 0.19    |
| AYPGKF, AU | 60 (44-83)          | 64 (45-78)          | 0.96    |

Continuous data are shown as median (interquartile range), AU, aggregation units.
In accordance with data from others, the rate of HRPR ADP was low in prasugrel-treated patients, and HRPR ADP was not seen in patients on ticagrelor, findings that differ from patients receiving clopidogrel. Clopidogrel-treated subjects exhibit inadequate P2Y₁₂ inhibition in up to 15% if ADP-inducible platelet aggregation is assessed by MEA. This is most likely due to the fact that clopidogrel is a prodrug requiring 2 steps of hepatic biotransformation to become pharmacologically active, while prasugrel needs only 1 step of hepatic metabolism and ticagrelor acts directly without prior modification. Its complex metabolism predisposes clopidogrel-mediated platelet inhibition to alteration by various factors like genetic polymorphisms, co-medication, age, sex, hemoglobin levels, renal function, smoking, and obesity. In contrast to clopidogrel, prasugrel and ticagrelor provide a stronger and more consistent antiplatelet effect. However, Bonello et al reported HRPR ADP in 25.2% of 301 prasugrel-treated ACS patients. The discrepancy between their findings and ours may be explained by the timing of testing: While Bonello et al measured platelet response to ADP immediately after administration of the prasugrel loading dose, we determined on-treatment platelet aggregation 72 hours after PCI. We chose this approach to capture the steady state of platelet inhibition by prasugrel and ticagrelor. Moreover, we assessed the response to prasugrel and ticagrelor by MEA, while Bonello et al used the vasodilator-stimulated phosphoprotein phosphorylation assay. As previously shown, different test systems for the determination of on-treatment platelet reactivity correlate at best moderately with each other.

Current literature rarely addresses PAR-mediated platelet aggregation in patients with adequate inhibition of the P2Y₁₂ receptor. In 2012, Kreutz et al showed that clopidogrel nonresponders also exhibit an increased platelet response to PAR-1 stimulation in 55 patients undergoing elective PCI. Likewise, we previously observed higher levels of PAR-1-mediated platelet surface P-selectin expression, activated glycoprotein IIb/IIIa and monocyte-platelet aggregate formation in thienopyridine nonresponders compared to patients with adequate clopidogrel and prasugrel mediated platelet inhibition. In addition, we found preserved PAR-1 and PAR-4 mediated platelet aggregation in the majority of clopidogrel-treated patients and in about 20% of prasugrel-treated patients with adequate ADP P2Y₁₂ inhibition. However, our previous studies comprised only 14 and 19 prasugrel-treated patients, respectively, and no patients on ticagrelor therapy. Accordingly, our previous results had to be considered as hypothesis generating only regarding platelet aggregation via PAR-1 and PAR-4 in patients on potent P2Y₁₂ inhibitors. Moreover, in contrast to the present investigation in ACS patients, the patients examined in the previous studies by others and us were all stable and underwent elective angioplasty and stenting.
Interestingly, in the present investigation, more prasugrel- and ticagrelor-treated patients showed a normal aggregation response following PAR-4 stimulation than following PAR-1 stimulation. This could partially be explained by the different concentrations of the PAR-1 agonist SFLLRN and the PAR-4 agonist AYPGKF used in our study. However, since PAR-4 requires higher concentrations of thrombin than PAR-1 in order to be activated, a higher AYPGKF concentration is necessary to achieve detectable PAR-4 mediated platelet aggregation.\textsuperscript{11,37} Another aspect is that PAR-4-mediated platelet aggregation differs with respect to ethnicity: In black populations, a high frequency of the gene variant PAR4-Thr120 has been reported, which is associated with greater signaling and platelet aggregation via PAR-4.\textsuperscript{38} However, all patients included in our study were of Caucasian ethnicity.

Vorapaxar is a highly selective antagonist of PAR-1, reversibly blocking thrombin-inducible platelet activation.\textsuperscript{39–41} In the phase III TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome) trial, vorapaxar on top of dual antiplatelet therapy did not reduce the primary composite end point of myocardial infarction (MI), urgent coronary revascularization, stroke, recurrent ischemia with rehospitalization, and death from cardiovascular causes in 12 944 patients with non-ST-elevation ACS.\textsuperscript{42} However, the key secondary end point consisting of death from cardiovascular causes, MI, or stroke was significantly reduced in patients on vorapaxar compared to placebo (14.1% vs. 12.7%; \(P = 0.02)\textsuperscript{42}

In the TRA\textsuperscript{2}P (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events)-TIMI 50 trial, vorapaxar in addition to standard antiplatelet therapy significantly reduced the composite end point of cardiovascular death, MI and stroke at 3 years in 26 449 patients with a history of ACS, ischemic stroke, or peripheral artery disease (PAD).\textsuperscript{43} On the other hand, major bleeding events including intracranial hemorrhage were significantly increased in patients receiving vorapaxar in both trials.\textsuperscript{52,43} Consequently, vorapaxor should not be prescribed in all ACS patients but may become a treatment option for patients with a high risk of ischemic cardiovascular events and a low bleeding risk.

In a previous study, we showed that high on-treatment PAR-1-mediated platelet activation is a strong predictor of ischemic outcomes in PAD patients following peripheral angioplasty and stenting.\textsuperscript{44} Furthermore, in a post hoc analysis of the TRA\textsuperscript{2}P-TIMI-50 trial, vorapaxar demonstrated its positive effects on adverse ischemic events vs. placebo in PAD patients.\textsuperscript{45}

Based on our observation of preserved platelet aggregation via PAR-1 in many prasugrel- and ticagrelor-treated patients, one may speculate that the measurement of PAR-1-mediated platelet aggregation may allow the identification of ACS patients who might benefit from additional vorapaxor therapy despite being already treated with potent P2Y\textsubscript{12} inhibitors. Moreover, PAR-4 might be a potential new target for antiplatelet therapy in patients with high PAR-mediated platelet aggregation.\textsuperscript{11,11} Indeed, it has recently been shown that PAR-4 antagonism reduces thrombin response by >50%.\textsuperscript{44–48} It must be taken into account that a combination of vorapaxor with stronger P2Y\textsubscript{12} inhibitors might impact on bleeding as also a combination of vorapaxor with glycoprotein IIb/IIIa inhibitors was associated with increased bleeding events.\textsuperscript{49} Accordingly, prospective clinical trials are necessary before such combination therapies can be considered.

Finally, inhibition of thrombin generation by addition of a low dose of the factor Xa inhibitor rivaroxaban to dual antiplatelet therapy with aspirin and clopidogrel was shown to reduce ischemic outcomes and death in 15 526 ACS patients in the ATLAS ACS 2-TIMI 51 (An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome) trial.\textsuperscript{50} As in the phase III trials investigating vorapaxor, the rates of major and intracranial bleeding were higher in the rivaroxaban groups than in patients receiving placebo.\textsuperscript{50}

Given the above-described literature on adding antithrombotic medications to standard treatment, proper patient selection (high ischemic and low bleeding risk) will be key for the success of an intensified antithrombotic regimen following ACS and PCI. Testing for PAR responsiveness may therefore become a future option to identify patients at high risk of ischemic events during state-of-the-art antiplatelet therapy, who might benefit from additional antithrombotic treatment. For this approach, however, clinical studies associating PAR-mediated platelet aggregation with adverse outcomes after PCI are needed.

Limitations of our study are the lack of clinical outcome data, its observational design, and the fact that we measured platelet aggregation at only 1 time point using a single test system. Moreover, we did not perform in vivo analyses. However, MEA is a highly standardized platelet function test ensuring a good comparability of the obtained results with other laboratories, and platelet aggregation by MEA has repeatedly been linked to cardiovascular outcomes following PCI.\textsuperscript{20,21} Another limitation of our study is that the cutoff values for PAR-1- and PAR-4-mediated platelet aggregation were derived from measurements in healthy volunteers, who were not on any medication and not age-matched to the patient population. However, by defining the upper 95% of PAR-mediated platelet aggregation in the control group as normal uninhibited platelet aggregation, we eliminated possible low outliers.

Finally, it must be mentioned that studies trying to individualize antiplatelet therapy based on platelet function testing have failed so far.

In conclusion, normal platelet aggregation via PAR-1 and PAR-4 is preserved in many ACS patients despite adequate P2Y\textsubscript{12} inhibition by prasugrel and ticagrelor. The present findings may in part explain the occurrence of adverse ischemic events despite potent P2Y\textsubscript{12} inhibition. Future trials are warranted to investigate the association of PAR-mediated platelet aggregation with clinical outcomes in ACS and to study potential therapeutic approaches.

ACKNOWLEDGMENTS

The research was funded by the “Medical Scientific Fund of the Mayor of the City of Vienna,” grant number 14016, and by the
"Anniversary Fund of the Austrian National Bank," grant number 16155, to Thomas Gremmel.

**RELATIONSHIP DISCLOSURE**

The authors report nothing to disclose.

**AUTHOR CONTRIBUTIONS**

PPW: data collection, performance of measurements, and writing of the manuscript. JP and CW: data collection, critical revision, and final approval of the manuscript. BE: performance of measurements, critical revision, and final approval of the manuscript. BP: data collection, writing of the manuscript, critical revision, and final approval of the manuscript. KH, IML and RK: critical revision and final approval of the manuscript. SP: study design, critical revision, and final approval of the manuscript. TG: study design, statistical analysis, writing of the manuscript, critical revision, and final approval of the manuscript.

**ORCID**

Patricia P. Wadowski https://orcid.org/0000-0003-2462-4515

Thomas Gremmel https://orcid.org/0000-0001-9554-7292

**REFERENCES**

1. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al.; ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267–315.

2. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77.

3. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al.; ESC Scientific Document Group, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease development in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213–60.

4. Gremmel T, Michelson AD, Frelinger AL III, Bhatt DL. Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost. 2018;2:439–49.

5. P ultar J, Wadowski PP, Panzer S, Gremmel T. Oral antiplatelet agents in cardiovascular disease. Vasa. 2018;1–12. https://doi.org/10.1024/0301-1526/a000753. [Epub ahead of print]

6. Wirvovt SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.

7. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.

8. Motovska Z, Hlinomaz O, Kala P, Hromadka M, Knot J, Varvarovsky I, et al. 1-year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor. J Am Coll Cardiol. 2018;71:371–81.

9. Gremmel T, Frelinger AL 3rd, Michelson AD. Platelet physiology. Semin Thromb Hemost. 2016;42:191–204.

10. Kahn ML, Nakamichi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999;103:879–87.

11. Duvernay MT, Temple KJ, Maeng JG, Blobaum AL, Stauffer SR, Lindsay CW, et al. Contributions of protease-activated receptors PAR1 and PAR4 to thrombin-induced GP IIb/IIIa activation in human platelets. Mol Pharmacol. 2017;91:39–47.

12. Ofosu FA, Dewar L, Craven SJ, Song Y, Cedrone A, Freedman J, et al. Coordinate activation of human platelet protease-activated receptor-1 and -4 in response to subnanomolar alpha-thrombin. J Biol Chem. 2008;283:26886–93.

13. Martorell L, Martinez-Gonzalez J, Gentile M, Calvayrac O, Badimon L. Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb Haemost. 2008;99:305–15.

14. Wu CC, Wu SY, Liao CY, Teng CM, Wu YC, Kuo SC. The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation. Br J Pharmacol. 2010;161:643–58.

15. Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW, Davie EW. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci U S A. 1999;96:11189–93.

16. Vretenbrant K, Ramstrom S, Bjerke M, Lindahl TL. Platelet activation via PAR4 is involved in the initiation of thrombin generation and in clot elasticity development. Thromb Haemost. 2007;97:417–24.

17. Kreutz RP, Breall JA, Kreutz Y, Owens J, Lu D, Bolad I, et al. Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response. Thromb Res. 2012;130:198–202.

18. Badr Eslam R, Lang IM, Koppensteiner R, Calatzis A, Panzer S, Gremmel T. Residual platelet activation through protease-activated receptors (PAR)-1 and -4 in patients on P2Y12 inhibitors. Int J Cardiol. 2013;168:403–6.

19. Verstraete M. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs. 1990;40:498–530.

20. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, et al.; Working Group on On-Treatment Platelet Reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261–73.

21. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2009;53:849–56.

22. Sibbing D, Morath T, Braun S, Stegherr J, Mehilli J, Vogt W, et al. Clopidogrel response status assessed with Multplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost. 2010;103:151–9.

23. Mayer K, Bernlochner I, Braun S, Schulz S, Orban M, Morath T, et al. Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. J Am Coll Cardiol. 2014;64:863–71.

24. Aradi D, Kilczkowski W, Atar D, Serebruany VL. Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. Thromb Haemost. 2012;107:338–45.
25. Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLAtelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol. 2010;56:1456–62.

26. Lemesle G, Schurtz G, Bauters C, Hamon M. High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. J Thromb Haemost. 2015;13:931–42.

27. Michelson AD. New P2Y12 antagonists. Curr Opin Hematol. 2009;16:371–7.

28. Gremmel T, Panzer S. Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. Thromb Haemost. 2011;106:211–8.

29. Wadowski PP, Kopp CW, Koppensteiner R, Lang IM, Pultar J, Lee S, et al. Decreased platelet inhibition by P2Y12 receptor blockers in anaemia. Eur J Clin Invest. 2018;48. https://doi.org/10.1111/eci.12861.

30. Bonello L, Pansieri M, Mancini J, Bonello R, Maillard L, Barnay P, et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol. 2011;58:467–73.

31. Bonello L, Mancini J, Pansieri M, Maillard L, Rossi P, Collet F, et al. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. J Thromb Haemost. 2012;10:1999–2005.

32. Floyd CN, Passacquale G, Ferro A. Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications. Clin Pharmacokinet. 2012;51:429–42.

33. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost. 2009;101:333–9.

34. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. Thromb Res. 2011;128:352–7.

35. Gremmel T, Calatzis A, Steiner S, Kaider A, Seidinger D, Koppensteiner R, et al. Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel? Platelets. 2010;21:515–21.

36. Gremmel T, Kopp CW, Seidinger D, Koppensteiner R, Steiner S, Panzer S. Preserved thrombin-inducible platelet activation in thienopyridine-treated patients. Eur J Clin Invest. 2013;43:689–97.

37. Covic L, Gresser AL, Kilupulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry. 2000;39:5458–67.

38. Edelstein LC, Simon LM, Lindsay CR, Kong X, Teruel-Montoya R, Tourdort BE, et al. Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Blood. 2014;124:3450–8.

39. Leonardi S, Tricoci P, Becker RC. Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555. Drugs. 2010;70:1771–83.

40. Judge HM, Jennings LK, Moliterno DJ, Hord E, Ecob R, Tricoci P, et al. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact. Platelets. 2015;26:236–42.

41. Chackalamannil S. Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong anti-platelet effects. J Med Chem. 2006;49:5389–403.

42. Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366:20–33.

43. Morrow DA, Braunwald E, Bonaca MP, Ameris SF, Dalby AJ, Fish MP, et al.; TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404–13.

44. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation. Thromb Haemost. 2014;111:474–82.

45. Bonaca MP, Scirica BM, Creager MA, Olin J, Bounaumehaux H, Dellborg M, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2(degrees)P-TIMI 50. Circulation. 2013;127:1522–9 e9-1-6.

46. Grover SP, Bergmeier W, Mackman N. Platelet signaling pathways and new inhibitors. Arterioscler Thromb Vasc Biol. 2018;38:e28–35.

47. Wong PC, Seiffert D, Bird JE, Watson CA, Bostwick JS, Giancarli M, et al. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Sci Transl Med. 2017,9. https://doi.org/10.1126/scitranslmed.aaf5294.

48. Wilson SJ, Ismat FA, Wang Z, Cerra M, Narayan H, Raftis J, et al. PAR4(protease-activated receptor 4) antagonism with BMS-986120 inhibits human ex vivo thrombus formation. Arterioscler Thromb Vasc Biol. 2018;38:448–56.

49. Cornel JH, Tricoci P, Lokhnygina Y, Moliterno DJ, Wallentin L, Armstrong PW, et al. Glycoprotein IIb/IIIa receptor inhibitors in combination with vorapaxar, a platelet thrombin receptor antagonist, among patients with non-ST-segment elevation acute coronary syndromes (from the TRACER trial). Am J Cardiol. 2015;115:1325–32.

50. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9–19.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.